A revolutionary experimental treatment is showing “unprecedented” results in treating Stiff Person Syndrome (SPS), a rare and debilitating autoimmune disorder. Results presented at the annual American Academy of Neurology meeting in Chicago suggest that a new cell therapy could do more than just manage symptoms—it could potentially restore lost mobility.
Understanding Stiff Person Syndrome
Stiff Person Syndrome is a rare neurological condition affecting an estimated 5,000 people in the United States. The disorder is characterized by:
– Severe muscle stiffness and intense, involuntary contractions.
– Chronic pain and spasms powerful enough to cause bone fractures.
– Loss of mobility, often leading patients to rely on walkers or wheelchairs.
The root cause of SPS is an autoimmune malfunction where the body’s own antibodies attack the brain and spinal cord. Currently, there are no FDA-approved treatments specifically for SPS. Existing therapies focus on symptom management or use drugs approved for other diseases, but these often provide limited relief and fail to stop the progressive decline in physical function.
A “Factory Reset” for the Immune System
The experimental drug, known as miv-cel, represents a fundamental shift in how doctors approach autoimmune diseases. Developed by Kyverna Therapeutics, the treatment utilizes CAR T cell therapy —a technique originally pioneered in oncology to fight cancer.
Instead of merely suppressing the immune system, miv-cel works by:
1. Targeting B cells, which act as the “factories” for harmful antibodies.
2. Eliminating these cells to effectively clear the body of the rogue antibodies causing the disease.
3. Providing a “factory reset” for the immune system, aiming to stop the attack at its source.
Remarkable Clinical Results
In a Phase II clinical trial involving 26 patients, the results were described by neurologist Amanda Piquet as “truly remarkable.” The data suggests that the therapy provides consistent and significant functional improvements:
- Improved Mobility: Four months after a single infusion, patients showed measurable increases in walking speed.
- Reduced Dependency: Of the 12 patients who previously required walking aids, eight were able to walk without them following treatment.
- Life-Changing Recovery: In one documented case, a patient transitioned from using a walker to being able to run during his last follow-up.
Challenges and Next Steps
While the results are promising, the therapy is not without risks and unknowns. The most common serious side effect reported was a low white blood cell count. Additionally, researchers have yet to determine if a single infusion is sufficient or if multiple treatments will be necessary to maintain long-term remission.
“The magnitude and consistency of functional improvement observed is unprecedented.” — Dr. Amanda Piquet, University of Colorado Anschutz
If the therapy receives regulatory clearance, it would mark a historic milestone: the first CAR T cell therapy approved for an autoimmune disease, potentially opening the door for similar treatments for other complex immune disorders.
Looking Ahead: Kyverna Therapeutics plans to submit miv-cel for FDA approval in the first half of 2026.
Conclusion: By targeting the underlying cause of Stiff Person Syndrome rather than just its symptoms, miv-cel offers a potential paradigm shift in treating autoimmune disorders, moving from management toward functional recovery.
